Inhibikase Therapeutics
IKT
11 hedge funds and large institutions have $299K invested in Inhibikase Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
4.22% less ownership
Funds ownership: 8.03% → 3.81% (-4.2%)
15% less funds holding
Funds holding: 13 → 11 (-2)
50% less capital invested
Capital invested by funds: $598K → $299K (-$299K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$8.59K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.85K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.07K |
| 4 |
William Blair & Company
Chicago,
Illinois
|
+$924 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$64 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$259K |
| 2 |
Edgewood Management
Greenwich,
Connecticut
|
-$23.2K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.59K |
| 4 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
-$1.38K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$207 |
IKT Hedge Fund Activity: Q4 2023 in Review
11 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q4 2023, worth a combined $299K — down 50% from $598K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IKT and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $8.59K. The largest seller was Armistice Capital, exiting entirely with an estimated $259K sold.
- 11 institutional investors held Inhibikase Therapeutics (IKT) as of Q4 2023, down from 13 in Q3 2023.
- Funds reported $299K of Inhibikase Therapeutics stock for Q4 2023, down 50% quarter-over-quarter.
- 2 funds opened new Inhibikase Therapeutics positions in Q4 2023 and 4 closed out, a net change of -2 holders.
- The largest Inhibikase Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $8.59K added.
- The largest Inhibikase Therapeutics seller in Q4 2023 was Armistice Capital, an estimated $259K sold.
Based on aggregated 13F filings for Q4 2023.